Eli Lilly announced on Tuesday morning that it would buy Prevail Therapeutics in a deal potentially valued at $1.04 billion, in order to expand its presence in the gene therapy field.
Eli Lilly announced on Tuesday morning that it would buy Prevail Therapeutics in a deal potentially valued at $1.04 billion, in order to expand its presence in the gene therapy field.